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Abstract  
Introduction: Sub-optimal adherence constitutes a significant impediment to the management of severe mental illnesses (SMIs) as it negatively 
impacts on the course of the illness and the treatment outcome. In this study, the levels of adherence, prevalence and the predictors of sub-
optimal adherence were assessed in a sub-Saharan African setting. Methods: Three hundred and seventy (370) respondents with diagnoses of 
schizophrenia, bipolar disorder or severe depression were randomly enrolled and interviewed at the out-patient department of the Federal 
Neuropsychiatric Hospital, Maiduguri in northeastern Nigeria. An anonymous sociodemographic questionnaire and a clinical proforma designed by 
the authors, Oslo social support scale and the 8-item Morisky Medication Adherence Scale (MMAS-8) were used for data collection. Results: The 
prevalence of sub-optimal adherence was 55.7%. The independent predictors of sub-optimal adherence were; seeking for traditional/ spiritual 
treatment (Odds Ratio (O.R.) = 6.523, 95% C.I. = 3.773 - 11.279, P = < 0.001), male gender (O.R. = 3.307, 95% C.I. = 1.907 - 5.737, P = < 
0.001), low levels of insight (O.R. = 1.753, 95 C.I. = 1.220 - 2.519, P = 0.002), and low social support levels (O.R. = 1.528, 95% C.I. = 1.097 - 
2.129, P = 0.012). Conclusion: Based on the outcome of the study, we recommend the development of psycho-educational programmes on 
adherence and the active involvement of the relations and significant others in the management of patients with SMIs in sub-Saharan Africa. 
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Introduction 
 
The severe mental illnesses (SMIs) are characterized by a chronic, 
and sometimes, fluctuating course as well as their association with 
significant functional impairments/disabilities [1-4]. The main aims 
of managing such disorders are to achieve and maintain remission 
of symptoms and, to reduce the accompanying impairments [5]. 
Psychotropic medications together with other non-pharmacological 
modalities constitute the cornerstones in the management of these 
disorders as espoused by the biopsychosocial model [6]. Since the 
SMIs are chronically disabling, their management specifically with 
medications are also longstanding and in some cases lifelong. A key 
determinant of the success of pharmacotherapy in patients with 
SMIs is their adherence to the medication regimen, which is defined 
as the extent to which medication intake behaviour corresponds 
with the recommendations of the health care provider [7-10]. 
Hence, non-adherence to medications (treatment) is the degree to 
which the patient does not carry out the clinical recommendations 
of a treating physician. Non-adherence to medications is a complex 
and multidimensional healthcare problem as it constitutes a major 
obstacle to translating treatment efficacy in research settings into 
effectiveness in clinical practice [11-13]. Research evidences abound 
that have shown its clinical significance on the course of the illness 
and treatment outcomes [14-16]. In addition, there can be a 
profound impact on the cost of care, as well as significant 
impediments to the patients´ long term adaptations, including the 
social, vocational and academic functioning [17,18]. 
  
Globally, non-adherence rates among patients with severe mental 
illness ranged between 30% and 65% [19-21]. In schizophrenia, 
the average rate is about 50%, with a range of 4% to 74% [22-24]. 
In bipolar disorders, the non-adherence rate to long term 
prophylactic pharmacotherapy was between 20% and 66% [25-27]. 
In unipolar depression, the estimated non-adherence rates ranged 
from 13% to 52.7% [28-31]. The reported rates for non-adherence 
were 41.2% in Ethiopia and 74% in Egypt on the African continent 
[32, 33]. In Nigeria, the recorded rates of non-adherence among 
patients with SMIs ranged from 48% to 55.5% in Southern Nigeria, 
and 49.4% in Kaduna and 34.2% in Jos, North-western and North-
central Nigeria respectively [34-37]. Sub-optimal adherence in 
psychiatric populations may be attributed to multifactorial influences 
Such as; age, gender, poor insight, negative attitude towards 
medications, shorter duration of illness, poor therapeutic alliance 
and poor social support [19,21,27,34]. Africans, have their 
psychological and social peculiarities with regards to mental illnesses 
and such variables could affect their adherence to pharmacotherapy 
in the context of severe mental illnesses. Each African setting has its 
own peculiarities in terms of belief systems and social support as 
well as their effects on health seeking and adherence. To the best 
of our knowledge, this is the first study from North-eastern Nigeria 
that addresses this topical issue among patients with SMIs as a 
prototype sub-Saharan setting. It sought to ascertain; 1) the levels 
of adherence to pharmacotherapy among patients with severe 
mental illnesses and 2) determine the sociodemographic and clinical 





Study design and setting 
  
This was a hospital-based cross-sectional study conducted at the 
outpatient department of the Federal Neuropsychiatric Hospital, 
Maiduguri, Borno State, Nigeria. As a matter of policy, all diagnoses 
made in the institution were according to the tenth edition of the 
International Classification of Diseases and health-related disorders 
(ICD - 10) criteria. Clinically generated data for each subject 
enrolled were matched to the ICD -10 criteria by Consultant 




The sample size was calculated using a prevalence rate of 49.4% 
for non-adherence among patients with mental illnesses in northern 
Nigeria as reported by Adeponle et al. (2009), which was set at 
95% confidence interval and 0.05 degree of precision [36]. This 
yielded a minimum sample size of 380 but a total of 390 
respondents were interviewed in order to enhance the power of the 
study. Hence, one hundred and thirty (130) subjects each, with the 
diagnoses of; schizophrenia, bipolar disorder and severe unipolar 
depression were enrolled for the study. Patients were randomly 
selected using the table of random numbers during their respective 
clinic visitations. The eligibility criteria were: A diagnosis of 
Schizophrenia, bipolar disorder or severe unipolar depression, had 
been on medications for at least 6 months, adults above the age of 
18years, and who granted consent. The exclusion criteria were: 
current florid psychopathology capable of impairing response, and 
comorbid psychoactive substance use or physical disorders. For the 
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purpose of screening out those with significant psychopathology, 
mental state examination was conducted on all the participants at 
the index contact. Based on the outcome of this clinical evaluation 
alone, those that could not be engaged are excluded. While the 
exclusion of those with a comorbid physical disorder was based on 
previous clinical documentation, symptoms at presentation, general 
physical and relevant systemic examinations. All of the above clinical 





Data collection spanned between February and August, 2014, and 
the following standardized quantitative assessment tools were 
used: (i) Socio demographic questionnaire designed by the authors 
that solicited for age, sex, marital status and occupational status by 
using the social class stratification by Borofka and Olatawura [38]. 
This system classified individuals based on their occupations into: 
social class I (highly skilled respondents like Doctors, Lawyers, etc), 
social class II (intermediate skilled respondents like technicians, 
nurses, etc), social class III (low-skilled respondents like drivers, 
junior clerks, etc), social class IV (unskilled respondents like petty 
traders, messengers, etc) and finally social class V (unskilled 
respondents). It also asked about the respondents´ beliefs about 
the aetiology of mental illness.(ii) Clinical proforma also designed 
by the authors that sought for clinical information like diagnosis and 
duration of treatment as well as other forms of treatment sought 
and the degree of insight based on current assessment. For the 
assessment of insight the following dichotomous questions were 
asked and a score of 1 is assigned for yes and a score of zero for no 
for any item answered: Do you accept that you have an illness? Do 
you think that you require treatment? And, do you think you require 
your medications to stay well? The total score range between 0 and 
3. A total score of zero is regarded as "no insight", total score of 1-2 
is "partial insight", and a total score of 3 is interpreted as "full 
insight". (iii) Oslo social support scale which is a 3-item scale that 
assesses the level of an individual's social support. The scale asks 
about the ease of getting help from neighbours, the number of 
people the subjects can count on when there are serious problems, 
and the level of concern people show in what the subject is doing. 
The instrument has been validated for use in Nigeria [39]. A sum 
index is obtained by adding the raw scores of the three items. The 
range is 3-14. The scores are interpreted as follows; 3-8 (poor social 
support), 9-11 (moderate social support), and 12-14 (strong social 
support) [40]. (iv) Morisky medication adherence scale (MMAS-8) 
which is an 8-item instrument which was developed by Donald 
Morisky to assess medication adherence among patients with 
different clinical conditions. In interpreting the outcome, the scores 
are graded as follows: <6 is low adherence, 6 to <8 is medium 
adherence and high adherence is equal to 8 [41]. For the purpose 
of this study, sub-optimal adherence is defined as MMAS-8 score of 
less than 8 while score of 8 is considered adherent. Similar cut-off 
score was adopted for non-adherence among hypertensive 




Ethical clearance was obtained from the institutional review board of 
Federal Neuropsychiatric Hospital, Maiduguri. Written informed 
consents were also obtained from all the participants. In order to 




The data were analyzed using statistical package for social sciences 
(SPSS) version 20. Descriptive statistics were used to represent the 
characteristics of the participants. Bivariate analyses were used to 
explore the associations between the psychosocial variables and 
sub-optimal medication adherence among the participants. Binary 
logistic regression was then conducted to determine the 
independent predictors of sub-optimal adherence among the 
subjects. Sub-optimal adherence was used as independent variable 
while the factors found to be significant on bivariate analysis were 






Of the 390 respondents enrolled, the data of 370 respondents were 
finally analyzed yielding an overall response rate of 94.87%. The 
data of 20 respondents were not analyzed due to: refusal to grant 
informed consent (n=8), comorbid psychoactive substance use 
(n=5), presence of florid psychopathology, particularly, auditory 
hallucinations and delusions (n=5), and those whose questionnaires 
could not be analyzed due to missing data (n=2). In terms of the 
sociodemographic characteristics of the respondents: males 
constituted 56.5%, their ages ranged from 18 to 63 years with an 
average of 35.06 years (SD+ 9.63). Over 70% of the respondents 
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were ≤ 40 years of age. Semi-skilled and unskilled workers as well 
as the unemployed constituted over 60% of the respondents and 
about 51% were unmarried. About 43% of the respondents 
believed that mental illnesses were caused by either demonic 
possession or retribution for ´sins´ committed by one´s ancestors. 
The clinical characteristics of the respondents revealed that about 
63% 0f the respondents had their illnesses for less than or equal to 
4 years and nearly 56% of them had sought for either traditional 
African/spiritual forms of treatment apart from the conventional 
(orthodox) care. About 31% had poor social support while 69% had 
moderate to strong social support. About 58% had full insight, 
while, about 18% and 24% had no and partial insights respectively. 
  
Levels of adherence and prevalence of sub-optimal 
adherence 
One hundred and sixty eight (45.4%), thirty eight (10.3%), and one 
hundred and sixty four (44.3%) had low, medium and high levels of 
medication adherence respectively. The prevalence rate for sub-
optimal adherence was 55.7% using an MMAS score of <8 as 
adapted for this study. The findings are depicted in Table 1. 
  
Socio-demographic variables associated with sub-optimal 
adherence 
Of all the sociodemographic variables analysed for association with 
sub-optimal medication adherence only gender (χ2=50.415, df=1, 
p=<0.001) and belonging to lower occupational classes (χ2=57.93, 
df=4, p=<0.001) were found to be statistically significant. These 
are presented in Table 2. 
  
Clinical variables associated with sub-optimal adherence 
  
The clinical variables found to have statistically significant 
associations with sub-optimal medication adherence were: the 
diagnosis (χ2=44.217, df=2, p=<0.001), seeking for alternate forms 
of treatment (χ2=70.217, df=1, p=<0.001), low levels of social 
support (χ2=27.265, df=2, p=<0.001), and low levels of insights 
(χ2=24.705, df=2, p=<0.001). The findings are shown inTable 3. 
  
Logistic regression analysis for variables associated with 
sub-optimal adherence 
  
Logistic regression analyses revealed that only gender (Odds ratio 
(O.R.) = 3.307, p = <0.001, 95% C.I. = 1.907 - 5.737) and lower 
occupational classes (O.R. = 0.643, P = <0.001, 95% C.I. = 0.539 - 
0.767) were the independent predictors of sub-optimal adherence. 
While the independent clinical predictors were; diagnosis (O.R. = 
1.428, p = 0.037, 95% C.I. = 1.021 - 1.998), spiritual or traditional 
treatment seeking apart (O.R. = 6.523, p = <0.001, 95% C.I. = 
3.773 - 11.279), poor social support (O.R. = 1.528, p = 0.012, 95% 
C.I. = 1.097 - 2.129), and low levels of insight (O.R. = 1.753, p = 
0.002, 95% C.I. = 1.220 - 2.519). The findings are depicted 





This study assessed the levels of medication adherence and the 
psychosocial predictors of sub-optimal adherence among patients 
with SMIs in a tertiary mental health facility in north-eastern 
Nigeria. Though, other studies by Adeponle et al. (2009) and 
Danladi et al. (2013), addressed this issue in northern Nigeria, theirs 
were among patients with discrete diagnosis, mainly schizophrenia 
[36,37]. To the best of the authors' knowledge, this is the first study 
that addressed this topical issue among patients with diagnoses that 
cut across discrete clinical groups in this part of sub-Saharan Africa. 
The adherence rates were 45.4% for low adherence, 10.3% for 
medium adherence, and 44.3% for high adherence. This translates 
to about every one out of two of the subjects enrolled for the study 
had low adherence. This rate for non-adherence falls within the 
range of 30% to 65% estimated in previous studies by Yang et al. 
(2012), and Kassis et al. (2014) [20,21]. It is also similar to the 
rates of 48% and 49.4% reported by Adewuya et al. (2009) and 
Adeponle et al. (2009) in Nigeria [34, 36]. The prevalence rate of 
sub-optimal adherence was 55.7% as defined in the methodology of 
this study to be the cumulative total of low and medium adherence 
rates. The rate of high adherence of 44.3% recorded in this study 
was also within the range reported by Adewuya et al. (2009) [34]. 
  
Though, sub-optimal adherence rate is within the range of earlier 
quoted values, this figure is higher than the rates of 49.4% and 
38% reported by Adeponle et al. (2009), and Danladi et al. (2013) 
in northern Nigeria where the participants had similar 
sociodemographic characteristics [36,37]. It was, on the other hand, 
lower than the values of 66.9% and 74% reported in Egypt and 
India respectively [21,30]. In explaining this discrepancy, we 
advanced two possible explanations; first methodological differences 
in the studies, such as the tools used for the assessment of 
adherence and the different cut-off values used for the definition of 
adherence and non-adherence. Secondly, most of the previous 
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studies, used respondents with homogenous diagnosis, i.e., 
schizophrenia, bipolar disorder or unipolar depression discretely. In 
this study, the three heterogeneous groups were assessed which 
brought the peculiarities of the three conditions such as medication 
regimen(s) to bear simultaneously. Among the sociodemographic 
variables analyzed for possible association with sub-optimal 
adherence only gender and occupational class were independent 
predictors after logistic regression. Males were over 3 times more 
likely to be sub-optimally adherent when compared to females. 
Demoz et al. (2014) similarly found higher adherence rates among 
females in Jimma, Ethiopia [14]. In a comprehensive literature 
review, Lacro et al. (2002), concluded that gender was not a 
consistent predictor of non-adherence to treatment [22]. The higher 
adherence rate of 64% recorded in females could be attributed to 
the patriarchal nature of the study setting in which females are 
socially and culturally expected to be compliant, and this might 
positively affect their adherence in the therapeutic alliance. 
  
Analysis of occupational class as an independent predictor of sub-
optimal adherence showed that over 79% of the non-adherent 
subjects belonged to the semi-skilled, unskilled and unemployed 
classes. Over 55% of the adherent subjects on the other hand, were 
either skilled or intermediate skilled professionals. This finding is in 
tandem with that of Verdoux et al. (2000), who found lower 
occupational status to be a predictor of poor medication adherence 
among first admitted psychotic patients [43]. The plausible reasons 
for this are; (1) since affordability is critical to adherence with 
medications, those in the higher occupational classes might not be 
encumbered in this case, because of their economic strength. (2) 
They may also be better motivated to adhere to treatment protocols 
in order to retain their jobs. The independent clinical predictors of 
sub-optimal adherence in this study were; diagnoses, forms of 
treatment sought, levels of social support and insight. Based on the 
outcome, patients with a diagnosis of schizophrenia were over 3 
times more likely to be sub-optimally adherent than those with 
either bipolar disorder or unipolar depression. This might be 
attributed to residual symptomatology and difficulties with 
interpersonal adjustment that may be commoner in schizophrenia 
than either bipolar disorder or unipolar depression as reported by 
Fenton et al. (1997) [44]. In terms of treatment sought, seeking for 
traditional African/spiritual treatments apart from the 
conventional/orthodox care increases the likelihood of sub-optimal 
adherence by over 6 times. This is because seeking for traditional or 
spiritual interventions are more often accompanied by mythical 
aetiological beliefs and doubts about the efficacy of the conventional 
modalities. Secondly, most of the traditional or spiritual healers in 
sub-Saharan Africa as a precondition for their intervention routinely 
ask their clients to discontinue any form of "western medication". 
The additive effects of these factors negatively impacts on 
medication adherence. 
  
In terms of social support as an independent predictor, those with 
low levels of social support were about 2 times more likely to be 
sub-optimally adherent. This finding is in tandem with that of 
Fenton et al. (1997), Bolkan et al (2013), Rabinovitch et al. (2013), 
and Razali et al. (2014) that have all shown significant relationship 
between poor social support and medication non-adherence among 
psychiatric patients [44-47] . The possible reasons in this scenario 
are: (a) the family serves as a cue to action or reinforcing factor for 
drug adherence for psychiatric patients, (b) based on the social drift 
hypothesis, the chronic and disabling nature of most SMIs have 
negative implications on the socioeconomic statuses of the patients, 
therefore, the onus of purchasing the medications lies solely on the 
family and other members of the patients' social networks. Poor 
social support base, therefore, may be an obstacle to optimal 
adherence. 
  
A critical look at the level of insight as an independent predictor 
showed that those with lower levels of insight were about 2 times 
more likely to have sub-optimal adherence. Insight is the degree of 
conscious awareness of the presence of an illness. Since adherence 
has a positive correlation with illness awareness and health seeking, 
it means insight is a determinant of the significance a patient 
attaches to any form of treatment. The lack of it, therefore, 
undermines adherence. This finding is in tandem with that of Yen et 
al. (2005), Lincoln et al. (2007), Rocca et al. (2008), and Mohamed 
et al. (2009), that all reported relationships between insight and 
medication adherence among psychiatric patients [48-51]. 
  
Limitations of the study 
  
The limitations of the study were; (1) this is a questionnaire based 
study; objective methods of assessing adherence such as pill counts 
and metabolite bioassay could have been more reliable indicators of 
sub-optimal adherence (2) the cross-sectional nature of this study 
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Conclusion 
 
Over half of the participants in this study were sub-optimally 
adherent to their medications we, therefore, recommend: (1) 
developing psycho-educational programmes that will address the 
misconceptions about the aetiology and spectra of symptoms 
associated with severe mental illnesses, (2) the active involvement 
of relatives and significant others in treatment planning and 
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Table 1: Levels of adherence of the participants (N = 370) 
Levels of adherence Frequency (%) 
Low adherence 168 (45.4) 
Medium adherence 38 (10.3) 






























































Gender         
Male 150(72.8) 59(36.0) 209(56.5) χ2=50.417, df=1, 
p=<0.001++ Female 56(27.2) 105(64.0) 161(43.5) 
Age in years [Mean = 35.06 
years + 9.628 SD, Range = 18 - 63 
years] 
        
≤ 40 years 145(70.4) 126(76.8) 271(73.2) χ2= 1.933, df=1, 
p=0.164 ˃ 40 years 61(29.6) 38(23.2) 99(26.8) 
Occupational class         
Skilled 14(6.8) 58(35.4) 72(19.5) 
χ2=57.93. df=4, 
p=<0.001++ 
Intermediate 29(14.1) 32(19.5) 61(16.5) 
Semiskilled 17(8.3) 12(7.3) 29(7.8) 
Unskilled 44(21.4) 17(10.4) 61(16.5) 
Unemployed 102(49.5) 45(27.4) 147(39.7) 
Marital status         
Married 103(50.0) 78(47.6) 181(48.9) 
χ2=2.72, df=3, 
p=0.437 
Single 64(31.1) 50(30.5) 114(30.8) 
Widowed 16(7.8) 9(5.5) 25(6.8) 
Divorced 23(11.1) 27(16.4) 50(13.5) 
Aetiological beliefs         
Psychological 108(52.4) 103(62.8) 211(57.0) 
χ2=4.269, df=2, 
p=<0.118 
Demonic 65(31.6) 38(23.2) 103(27.8) 
Retribution 33(16.0) 23(14.0) 56(19.2) 
++ Statistically significant findings 
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Diagnoses         
Schizophrenia 99(48.1) 29(17.7) 128(34.6) 
χ2=37.279,df=2,p=<0.001++ Bipolar disorder 54(26.2) 70(42.7) 124(33.5) 
Sev. depression 53(25.7) 65(39.6) 118(31.9) 
Duration of illness (in 
years) 
        
< 2 years 72(35.0) 52(31.7) 124(33.5) 
χ2=0.677, df=2, p=0.713 3 - 4 years 58(28.2) 52(31.7) 110(29.7) 
> 5 years 76(36.9) 60(36.6) 136(36.8) 
Forms of treatment 
sought 
        
Tradnal/spiritual 155(75.2) 52(31.7) 207(55.9) 
χ2=70.217, df=1, p=<0.001++ 
Orthodox only 51(24.8) 112(68.3) 163(44.1) 
Level of social support         
Poor 79(38.4) 34(20.7) 113(30.6) 
χ2=27.265, df=2, p=<0.001++ Moderate 67(32.5) 39(23.8) 106(28.6) 
Strong 60(29.1) 91(55.5) 151(40.8) 
Level of insight         
No insight 49(23.8) 17(10.4) 66(17.8) 
χ2=24.705, df=2, p=<0.001++ Partial insight 61(29.6) 29(17.6) 90(24.3) 
Full insight 96(46.6) 118(72.0) 214(57.8) 
++ Statistically significant findings 
 
 
Table 4: Logistic regression analysis for variables associated with sub-optimal adherence 
Variables Standard Error 
Exp (B) 
Odds ratio 
95% C. I. 
Lower - Upper 
P - value 
Gender 0.281 3.307 1.907 - 5.737 <0.001++ 
Occupatn class 0.090 0.643 0.539 - 0.767 <0.001++ 
Diagnosis 0.171 1.428 1.021 - 1.998 0.037++ 
Treatment sought 0.279 6.523 3.773 - 11.279 <0.001++ 
Social support 0.169 1.528 1.097 - 2.129 0.012++ 
Level of insight 0.185 1.753 1.220 - 2.129 0.002++ 
++Statistically significant findings 
  
 
